Assessment of benign tumor burden by whole-body MRI in patients with neurofibromatosis 1.
暂无分享,去创建一个
Jan M Friedman | L. Kluwe | V. Mautner | B. Widemann | E. Dombi | J. Friedman | Brigitte C Widemann | Eva Dombi | Lan Kluwe | Victor-F Mautner | Florence A Asuagbor | Carsten Fünsterer | Ralf Wenzel | C. Fuensterer | Ralf Wenzel | C. Fünsterer
[1] Q. Yang,et al. Mortality in neurofibromatosis 1: an analysis using U.S. death certificates. , 2001, American journal of human genetics.
[2] L. Kluwe,et al. Constitutional NF1 mutations in neurofibromatosis 1 patients with malignant peripheral nerve sheath tumors , 2003, Human mutation.
[3] J. Zeller,et al. Association between benign and malignant peripheral nerve sheath tumors in NF1 , 2005, Neurology.
[4] S. Steinberg,et al. NF1 plexiform neurofibroma growth rate by volumetric MRI , 2007, Neurology.
[5] R. Hughes,et al. Evaluation of 18fluorodeoxyglucose positron emission tomography (18FDG PET) in the detection of malignant peripheral nerve sheath tumours arising from within plexiform neurofibromas in neurofibromatosis 1 , 2000, Journal of neurology, neurosurgery, and psychiatry.
[6] P. Combemale,et al. Intérêt de la tomographie par émission de positons au fluorodéoxyglucose 18 dans la détection des neurofibrosarcomes au cours de la neurofibromatose de type 1 , 2007 .
[7] V. Riccardi. The genetic predisposition to and histogenesis of neurofibromas and neurofibrosarcoma in neurofibromatosis type 1. , 2007, Neurosurgical focus.
[8] R. Hughes,et al. Neurofibromatous neuropathy in neurofibromatosis 1 (NF1) , 2004, Journal of Medical Genetics.
[9] D. Evans,et al. Malignant peripheral nerve sheath tumours in neurofibromatosis 1 , 2002, Journal of medical genetics.
[10] C. Pratt,et al. Neurofibromatosis type I and malignancy: review of 32 pediatric cases treated at a single institution. , 1994, Medical and pediatric oncology.
[11] R. Siebert,et al. Screening 500 unselected neurofibromatosis 1 patients for deletions of the NF1 gene , 2004, Human mutation.
[12] B. Fuchs,et al. Malignant peripheral nerve sheath tumors: an update. , 2005, Journal of surgical orthopaedic advances.
[13] W. Molenaar,et al. Malignant peripheral nerve sheath tumors in patients with and without neurofibromatosis. , 1995, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[14] H. Kehrer-Sawatzki,et al. High frequency of mosaicism among patients with neurofibromatosis type 1 (NF1) with microdeletions caused by somatic recombination of the JJAZ1 gene. , 2004, American journal of human genetics.
[15] S. Pilotti,et al. Elevated risk for MPNST in NF1 microdeletion patients. , 2003, American journal of human genetics.
[16] L. Kluwe,et al. Malignant peripheral nerve sheath tumors (MPNST) in neurofibromatosis type 1 (NF1): diagnostic findings on magnetic resonance images and mutation analysis of the NF1 gene. , 2005, Anticancer research.
[17] J. Tonsgard. Clinical manifestations and management of neurofibromatosis type 1. , 2006, Seminars in pediatric neurology.
[18] Ziv M. Williams,et al. Value of PET in the assessment of patients with neurofibromatosis type 1. , 2007, AJR. American journal of roentgenology.
[19] M. O'Doherty,et al. [18F]2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) as a diagnostic tool for neurofibromatosis 1 (NF1) associated malignant peripheral nerve sheath tumours (MPNSTs): a long-term clinical study. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[20] R. Ferner. Neurofibromatosis 1 and neurofibromatosis 2: a twenty first century perspective , 2007, The Lancet Neurology.
[21] S. Thomson,et al. Review Article : NF1 Mutations and Molecular Testing , 2002, Journal of child neurology.
[22] A. Maniker,et al. Malignant peripheral nerve sheath tumors. , 2007, Neurosurgical focus.
[23] D. Viskochil. Review Article : Genetics of Neurofibromatosis 1 and the NF1 Gene , 2002, Journal of child neurology.
[24] B. Korf,et al. The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. , 1997, JAMA.
[25] V. Mautner,et al. Spinal tumours in neurofibromatosis type 1: an MRI study of frequency, multiplicity and variety , 1999, Neuroradiology.
[26] B. Korf. Review Article : Clinical Features and Pathobiology of Neurofibromatosis 1 , 2002 .
[27] R. Herva,et al. Risk of malignancy and death in neurofibromatosis. , 1997, Archives of pathology & laboratory medicine.
[28] R. Fabrello. Recommendations for management , 1979 .
[29] K. Khosrotehrani,et al. Subcutaneous neurofibromas are associated with mortality in neurofibromatosis 1: A cohort study of 703 patients , 2005, American journal of medical genetics. Part A.
[30] J. Lefaucheur,et al. Neurofibromatosis 1-associated neuropathies: a reappraisal. , 2004, Brain : a journal of neurology.
[31] V. Riccardi,et al. Neurofibromatosis: Phenotype, Natural History and Pathogenesis , 1992 .
[32] A. Dachman,et al. CT imaging in adults with neurofibromatosis‐1 , 1998, Neurology.
[33] R. Buchert,et al. Prognostic relevance of FDG PET in patients with neurofibromatosis type-1 and malignant peripheral nerve sheath tumours , 2006, European Journal of Nuclear Medicine and Molecular Imaging.
[34] B. Scheithauer,et al. Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases , 1986, Cancer.
[35] D. Easton,et al. A prospective study of neurofibromatosis type 1 cancer incidence in the UK , 2006, British Journal of Cancer.
[36] R. Friedrich,et al. Malignant peripheral nerve sheath tumors (MPNST) in NF1-affected children. , 2007, Anticancer research.
[37] H. Kehrer-Sawatzki,et al. Extensively high load of internal tumors determined by whole body MRI scanning in a patient with neurofibromatosis type 1 and a non-LCR-mediated 2-Mb deletion in 17q11.2 , 2005, Human Genetics.